Engimmune Therapeutics AG, a biotech company based in Basel developing novel T-cell receptor (TCR)-based therapeutics, closed a CHF 15.5m seed financing round. The round was led by the investors Pureos Bio-ventures and Novo Holdings with incubation from BaseLaunch. The proceeds will be used to grow and develop T-cell receptor-based therapies for cancer treatments, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.
The VISCHER team advising the investors in this transaction included Matthias Staehelin (Partner), Vincent S. Reardon (Managing Associate) and Pauline Pfirter (Associate), all Corporate/M&A.